In a remarkable surge, Microbot Medical Inc. (NASDAQ: MBOT) has witnessed a significant 22% increase in its stock price, reaching $2.58 during Monday’s trading session. This
notable
uptick follows the company’s recent announcement of selling 4.26 million shares under an ATM agreement, resulting in gross proceeds of $4.82 million.
Moreover, Microbot Medical disclosed securing definitive agreements for a registered direct offering and a concurrent private placement, successfully raising approximately $7 million before fees and expenses. As part of this initiative, the company is set to sell 4 million shares of common stock at $1.75 per share while issuing short-term Series G preferred investment options that allow the purchase of up to 8 million additional shares at the same price over two years.
The exclusive placement agent for these transactions is H.C. Wainwright & Co., with an anticipated closing date around January 7th pending customary conditions. The generated funds will be allocated towards advancing the development and commercialization of Microbot’s LIBERTY Robotic System, expanding its IP portfolio applications, and supporting general corporate purposes.
For investors keen on engaging with Microbot Medical in the market – whether through share acquisition or taking positions against the company – there are multiple avenues to explore. Purchasing shares typically involves utilizing a brokerage account, where fractional shares can be acquired to own portions of stock without buying an entire share.
When considering Microbot Medical’s current trading price at $2.9 per share as per recent data, investing $100 could secure you approximately 34.48 shares in the company.
On the other hand, for those interested in betting against a company like Microbot Medical, accessing an options trading platform or finding a broker willing to facilitate shorting stocks is crucial. Shorting stocks involves borrowing shares from a broker to sell them on the market with hopes of profiting from a decline in share prices.
Microbot Medical has exhibited a 52-week high of $2.95 and a low of $0.82 based on data from Benzinga Pro, reflecting fluctuating trends within this period.
Trading confidently demands staying informed with insights and alerts derived from analyst ratings, complimentary reports, and real-time news impacting relevant stocks within your portfolio.
In conclusion, understanding key developments within companies like Microbot Medical alongside exploring diverse investment strategies equips investors with essential tools to navigate today’s dynamic financial landscape efficiently.
Leave feedback about this